Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study
Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. …
Benzinga ·
Benzinga
